My question, frrol, is for those Alzheimer's drugs that were consider successful in P2, did any of those have a efficacy end point in P2 and did it show in P2. If so, what happened in P3 with efficacy ... why wasn't it successful in that area in P3 ... where did that success go, hence the "up in smoke" term.
My inclination is that efficacy was not an end point in P2 as BP was too concerned with the safety factor of their drug offerings, e.g., Lilly's sola.
Thus, to those inferring or spouting that 2-73 is going to fail as did 99% of other Alzheimer's drugs, I ask where is the correlation between those drugs and 2-73, which has shown efficacy in at least 6 and upwards of 25 participants.
If those people can't point to any correlation, then the comparison of the 99% failures in P3 to 2-73 is invalid in drawing any conclusion as to 2-73's chances for success in P3.
News 
Market Data 
Discover 
